• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CenterWatch Commentary: PharmaNet Down in Rough Seas

CenterWatch Commentary: PharmaNet Down in Rough Seas

September 16, 2008
CenterWatch Staff

The contract research business has always been a bit choppy. Projects from drug sponsors often get delayed or canceled. It’s the nature of contract work. But quarterly results should not be as erratic as what PharmaNet Development Group announced late last week.

PharmaNet’s shares cratered more than 60% to $9 a share after the contract research organization (CRO) slashed its financial guidance for the year. The company expects a loss now, instead of a predicted profit, following the Sept. 12 announcement of $19 million in project cancellations.

Just a little more than month ago, PharmaNet released a positive second quarter earnings report. In its second quarter, the company swung to a profit with net income of $2.2 million, compared with a net loss of $4.5 million, in the prior year quarter. They blew away analysts’ estimates.

Then came the project cancellation bombshell. Yes, this CRO business can be choppy quarter to quarter, but PharmaNet’s ups and downs seem extreme.

“Nobody’s luck is this bad,” noted Dave Windley, healthcare equity analyst at Jefferies & Company.

Other CROs, usually larger global ones such as Covance, have been able to produce somewhat predictable results quarter in and quarter out. PharmaNet had the advantage of being in a select group of global CROs that were well positioned for future growth. The company may have lost that advantage for now.

Upcoming Events

  • 06Jun

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

  • 07Jun

    Developing World-Class SOPs: Optimizing Quality and Compliance

  • 08Jun

    Implementing ICH E8 R1 Recommendations Increases Site and Participant Relationship Scoring Measures

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing